Seeking Alpha

Ziopharm Oncology (ZIOP) is in talks with prospective partners to market palifosfamide, which...

Ziopharm Oncology (ZIOP) is in talks with prospective partners to market palifosfamide, which appears to have performed well in patients with metastatic soft tissue sarcoma in a Phase III trial. Ziopharm may sign a deal before the full study data is known, although the greater likelihood is after its release in March. Ziopharm's shares shot up 18% yesterday on news of the trial, and are now +2.1%.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)